We are live on
!
Find out more
1CM
1492 Capital Management Portfolio holdings
AUM
$263M
1-Year Est. Return
61.9%
This Fund
S&P 500
This Quarter
Est. Return
+7.84%
1 Year Est. Return
+61.9%
3 Year Est. Return
+187.15%
5 Year Est. Return
+242.53%
10 Year Est. Return
+2,731.07%
AUM
$129M
AUM Growth
-$979K
(-0.76%)
Cap. Flow
-$5.84M
Cap. Flow
% of AUM
-4.54%
Top 10 Holdings %
Top 10 Hldgs %
33.23%
Holding
123
New
13
Increased
21
Reduced
54
Closed
21
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CY
Cypress Semiconductor
CY
|
+$2.61M |
| 2 |
ELGX
Endologix Inc
ELGX
|
+$1.37M |
| 3 |
FNSR
Finisar Corp
FNSR
|
+$1.25M |
| 4 |
NBEV
NewAge, Inc. Common Stock (Delaware)
NBEV
|
+$879K |
| 5 |
SUM
Summit Materials, Inc. Class A Common Stock
SUM
|
+$826K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Saia
SAIA
|
+$3M |
| 2 |
Ameris Bancorp
ABCB
|
+$2.58M |
| 3 |
CPE
Callon Petroleum Company
CPE
|
+$1.84M |
| 4 |
CSFL
CenterState Bank Corporation Common Stock
CSFL
|
+$1.72M |
| 5 |
BEAT
BioTelemetry, Inc.
BEAT
|
+$972K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 29.51% |
| 2 | Healthcare | 13.95% |
| 3 | Industrials | 12.82% |
| 4 | Financials | 10.25% |
| 5 | Consumer Discretionary | 7.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
ANI Pharmaceuticals
ANIP
$1.86B
| $2.16M | 1.68% |
43,608
+1,010
| +2% | +$56.7K |
|
|
REN
27
DELISTED
Resolute Energy Corporaton
REN
| $2.03M | 1.58% |
50,307
-12,557
| -20% | -$541K |
|
28
TherapeuticsMD
TXMD
$23.8M
| $1.6M | 1.25% |
4,450
-947
| -18% | -$293K |
|
|
ELGX
29
DELISTED
Endologix Inc
ELGX
| $1.5M | 1.17% |
+20,753
| New | +$1.37M |
|
|
CTLP
30
DELISTED
Cantaloupe
CTLP
| $1.43M | 1.11% |
336,527
-5,796
| -2% | -$24.6K |
|
31
Columbus McKinnon
CMCO
$422M
| $1.4M | 1.09% |
56,527
+18,197
| +47% | +$479K |
|
32
8x8 Inc
EGHT
$279M
| $1.28M | 1% |
84,062
-29
| -0% | -$439 |
|
33
Raymond James Financial
RJF
$33.5B
| $1.2M | 0.94% |
23,681
-15
| -0.1% | -$763 |
|
34
MaxLinear
MXL
$5.19B
| $1.2M | 0.93% |
42,812
-15
| -0% | -$385 |
|
35
Olin
OLN
$2.53B
| $1.15M | 0.89% |
34,975
-134
| -0.4% | -$4.02K |
|
36
Shopify
SHOP
$168B
| $1.13M | 0.88% |
165,840
| – | – |
|
|
FCB
37
DELISTED
FCB Financial Holdings, Inc.
FCB
| $1.09M | 0.85% |
21,984
-237
| -1% | -$11.3K |
|
38
Ligand Pharmaceuticals
LGND
$5.77B
| $1.06M | 0.83% |
16,133
| – | – |
|
39
Nektar Therapeutics
NKTR
$2.39B
| $988K | 0.77% |
2,807
-1
| -0% | -$225 |
|
|
TSC
40
DELISTED
TriState Capital Holdings, Inc.
TSC
| $988K | 0.77% |
42,328
-2,589
| -6% | -$59.2K |
|
|
XRN
41
Chiron Real Estate Inc
XRN
$535M
| $949K | 0.74% |
20,905
+181
| +0.9% | +$7.82K |
|
|
NBEV
42
DELISTED
NewAge, Inc. Common Stock (Delaware)
NBEV
| $895K | 0.7% |
+216,691
| New | +$879K |
|
43
Covenant Logistics
CVLG
$1.04B
| $838K | 0.65% |
89,134
+38,528
| +76% | +$380K |
|
|
YELL
44
DELISTED
Yellow Corporation Common Stock
YELL
| $835K | 0.65% |
75,826
+31,092
| +70% | +$403K |
|
45
Merit Medical Systems
MMSI
$4.82B
| $819K | 0.64% |
28,333
+5,322
| +23% | +$149K |
|
46
Omnicell
OMCL
$1.88B
| $704K | 0.55% |
+17,329
| New | +$639K |
|
47
Primoris Services
PRIM
$4.06B
| $671K | 0.52% |
+28,889
| New | +$694K |
|
48
MiMedx Group
MDXG
$630M
| $663K | 0.52% |
69,543
+16,997
| +32% | +$144K |
|
|
IBTX
49
DELISTED
Independent Bank Group, Inc.
IBTX
| $659K | 0.51% |
10,242
| – | – |
|
50
Criteo
CRTO
$1.14B
| $626K | 0.49% |
12,526
| – | – |
|
Similar funds
KA
DEA
EAN
PIP
VIG
SC
L
LB
1492 Capital Management's Q1 2017 Portfolio in Review
As of Q1 2017, 1492 Capital Management held 123 positions worth $129M, down 0.76% from $130M the previous quarter. Its ten largest holdings account for 33% of the portfolio.
1492 Capital Management withdrew a net $5.84M in Q1 2017, closing 21 positions and reducing 54 holdings. Its most notable exit was Axos Financial, an estimated $777K position sold in full.
By sector, the portfolio is most concentrated in Technology at 30% of assets, up from 26% a quarter earlier, followed by Healthcare and Industrials.
Against the trend, 1492 Capital Management opened a new position in Endologix Inc worth $1.5M.
- 1492 Capital Management's largest Q1 2017 buy was Endologix Inc: 20,753 shares worth $1.5M.
- 1492 Capital Management added most to Cypress Semiconductor in Q1 2017, an estimated $2.61M increase.
- 1492 Capital Management's biggest Q1 2017 reduction was Saia, cutting an estimated $3M.
- 1492 Capital Management fully exited Axos Financial in Q1 2017, selling an estimated $777K.
- 1492 Capital Management's ten largest holdings make up 33% of its $129M portfolio in Q1 2017.
- 1492 Capital Management opened 13 new positions and closed 21 in Q1 2017.
- 1492 Capital Management's portfolio value fell 0.76% quarter-over-quarter to $129M.
Based on 1492 Capital Management's 13F filing for Q1 2017, filed 15 May 2017.